Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2011 1
2012 2
2020 1
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
Yang J, Liu K, Yang L, Ji J, Qin J, Deng H, Wang Z. Yang J, et al. Front Immunol. 2023 May 23;14:1174762. doi: 10.3389/fimmu.2023.1174762. eCollection 2023. Front Immunol. 2023. PMID: 37287976 Free PMC article.
BACKGROUND: Cancer stem cells (CSCs) play vital roles in lung adenocarcinoma (LUAD) recurrence, metastasis, and drug resistance. ...CONCLUSION: This study developed a novel cuproptosis-related stemness signature that can be used to predict the prognosis and immune landscap …
BACKGROUND: Cancer stem cells (CSCs) play vital roles in lung adenocarcinoma (LUAD) recurrence, metastasis, and drug resistance. ...C …
Combining autophagy and immune characterizations to predict prognosis and therapeutic response in lung adenocarcinoma.
Li Q, Xie D, Yao L, Qiu H, You P, Deng J, Li C, Zhan W, Weng M, Wu S, Li F, Zhou Y, Zeng F, Zheng Y, Zhou H. Li Q, et al. Front Immunol. 2022 Sep 13;13:944378. doi: 10.3389/fimmu.2022.944378. eCollection 2022. Front Immunol. 2022. PMID: 36177001 Free PMC article.
Increasing evidence has revealed the clinical importance of interactions between autophagy and immune status in lung adenocarcinoma. The present study evaluated the potential of autophagy-immune-derived biomarkers to predict prognosis and therapeutic response in patients w …
Increasing evidence has revealed the clinical importance of interactions between autophagy and immune status in lung adenocarcinoma. …
Identification of a coagulation-related signature correlated with immune infiltration and their prognostic implications in lung adenocarcinoma.
Yang S, Chen S, Zhao Y, Wu T, Wang Y, Li T, Fu L, Ye T, Hu YQ, Chen H. Yang S, et al. Thorac Cancer. 2023 Nov;14(33):3295-3308. doi: 10.1111/1759-7714.15121. Epub 2023 Oct 5. Thorac Cancer. 2023. PMID: 37795779 Free PMC article.
BACKGROUND: Lung adenocarcinoma (LUAD) is a fatal form of lung cancer with a poor prognosis. ...RESULTS: We developed an immune-related signature (CRRS) composed of COL1A2, F2, PLAUR, C4BPA, and P2RX1 in LUAD. CRRS was an independent risk factor for overall s …
BACKGROUND: Lung adenocarcinoma (LUAD) is a fatal form of lung cancer with a poor prognosis. ...RESULTS: We developed an immun …
New soluble angiopoietin analog of Hepta-ANG1 prevents pathological vascular leakage.
Liu P, Ryczko M, Xie X, Baardsnes J, Lord-Dufour S, Duroche Y, Hicks EA, Taiyab A, Sheardown H, Quaggin SE, Jin J. Liu P, et al. Biotechnol Bioeng. 2021 Jan;118(1):423-432. doi: 10.1002/bit.27580. Epub 2020 Oct 10. Biotechnol Bioeng. 2021. PMID: 32970320
Vascular leak is a key driver of organ injury in diseases, and strategies that reduce enhanced permeability and vascular inflammation are promising therapeutic targets. ...We refer to this new fusion protein biologic as Hepta-ANG1, which forms a stable heptamer and induces …
Vascular leak is a key driver of organ injury in diseases, and strategies that reduce enhanced permeability and vascular inflammation …
CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course.
Pius-Sadowska E, Niedźwiedź A, Kulig P, Baumert B, Sobuś A, Rogińska D, Łuczkowska K, Ulańczyk Z, Wnęk S, Karolak I, Paczkowska E, Kotfis K, Kawa M, Stecewicz I, Zawodny P, Machaliński B. Pius-Sadowska E, et al. Int J Mol Sci. 2022 Sep 26;23(19):11338. doi: 10.3390/ijms231911338. Int J Mol Sci. 2022. PMID: 36232655 Free PMC article.
Concentrations of select chemokines (CXCL8, CXCL10, CCL2, CCL3, CCR1) and complement factors (C2, C9, CFD, C4BPA, C5AR1, CR1) were examined at mRNA and protein levels with regard to a COVID-19 course (ICU vs. non-ICU group) and CMV status at different time intervals. ...
Concentrations of select chemokines (CXCL8, CXCL10, CCL2, CCL3, CCR1) and complement factors (C2, C9, CFD, C4BPA, C5AR1, CR1) were ex …
Proteomic characteristics of the treatment trajectory of patients with COVID-19.
Li X, Ding G, Li S, Liu C, Zheng X, Luo J, He S, Zeng F, Huang X, Zeng F. Li X, et al. Arch Virol. 2024 Mar 27;169(4):84. doi: 10.1007/s00705-024-05991-y. Arch Virol. 2024. PMID: 38532129
Across different treatment stages of COVID-19, five proteins-PI16, GPLD1, IGFBP3, KRT19, and VCAM1-were identified as potential molecular markers for dynamic disease monitoring. Furthermore, the proteins BTD, APOM, IGKV2-28, VWF, C4BPA, and C7 were identified as candidate …
Across different treatment stages of COVID-19, five proteins-PI16, GPLD1, IGFBP3, KRT19, and VCAM1-were identified as potential molecular ma …
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.
Okroj M, Hsu YF, Ajona D, Pio R, Blom AM. Okroj M, et al. Mol Immunol. 2008 Jan;45(1):169-79. doi: 10.1016/j.molimm.2007.04.025. Epub 2007 Jun 4. Mol Immunol. 2008. PMID: 17548110
However, membrane-bound inhibitors over-expressed by certain types of tumor cells restrict the cytotoxic activity of complement. Herein we report that non-small cell lung cancer (NSCLC) cells produce soluble complement inhibitors factor I (FI) and C4b-binding protein (C4BP …
However, membrane-bound inhibitors over-expressed by certain types of tumor cells restrict the cytotoxic activity of complement. Herein we r …
Analysis of Plasma Proteins Involved in Inflammation, Immune Response/Complement System, and Blood Coagulation upon Admission of COVID-19 Patients to Hospital May Help to Predict the Prognosis of the Disease.
di Flora DC, Dionizio A, Pereira HABS, Garbieri TF, Grizzo LT, Dionisio TJ, Leite AL, Silva-Costa LC, Buzalaf NR, Reis FN, Pereira VBR, Rosa DMC, Dos Santos CF, Buzalaf MAR. di Flora DC, et al. Cells. 2023 Jun 10;12(12):1601. doi: 10.3390/cells12121601. Cells. 2023. PMID: 37371071 Free PMC article.
Other proteins that could potentially be employed in therapies against COVID-19 but that so far have not been associated with the disease are CD5L, VDBP, A1BG, C4BPA, PGLYRP2, SERPINC1, and APOH. Targeting these proteins' pathways might constitute potential new therapies o …
Other proteins that could potentially be employed in therapies against COVID-19 but that so far have not been associated with the disease ar …
11 results